Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2004

View Archived Issues

Preliminary data on the protective effects of HBV-ISS vaccine in older adult subjects

Phase II study confirms the therapeutic benefits of AOD-9604 in obesity

LifeSciChannel.com interviews Ambit Biosciences at BIO-Europe 2004

sNDA seeks label expansion for Aceon

GSK to acquire Bexxar rights from Corixa

First data reported on the effects of PBI-1402 on red blood cell production in humans

Encouraging preliminary phase II data with Surfaxin in the management of ARDS

Titan initiates phase IIb study of DITPA for congestive heart failure

Lupin INDs approved in India

Update on the efficacy and safety of MDX-060 in CD30-positive lymphoma

Good tolerability profile found for DT388-IL-3 in AML

Phase I study for CRF1 receptor antagonist

Phase I/II trial for CYT006-AngQb for hypertension

Discovery and Esteve restructure strategic alliance

Yissum patent claims series of novel MMP-2 inhibitors

Theravance describes dual beta2-adrenoceptor agonists/muscarinic receptor antagonists

Novel series of PDE4 inhibitors for inflammatory conditions described in patent literature

New insulin secretagogues and their use covered in recent patent

Phosphodiesterase type 2 inhibitors prepared and tested by Altana

Kinase inhibitors in early development at ImClone

Novel nucleoside analogue shows potent activity in breast cancer model

AMN-107 active in imatinib-resistant chronic myelogenous leukemia

Improved PDE5 inhibitors selected for clinical studies on erectile dysfunction

ICL-670 effective in treating iron overload

Phase I evaluation of CG-53135 successful in cancer patients

Anticancer activity of KOS-953 further characterized in vitro and in vivo

LifeSciChannel.com interviews companies at BIO-Europe 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...